print Print    Share Share  
Weekly Email Weekly News Email   RSS Feed News RSS  

Feminist News


Feminist Majority Foundation Applauds Transfer of Mifepristone (RU 486) Patent Rights to Dr. Edouard Sakiz, Former Roussel Uclaf CEO

Anti-Abortion Boycott Backfires

The transfer of mifepristone (formerly known as RU 486) patent rights from Roussel Uclaf and Hoechst AG to Dr. Edouard Sakiz is good news for women worldwide.

Dr. Sakizs leadership as the CEO of Roussel Uclaf was largely responsible for the development of mifepristone as a safe, effective method of early abortion. With the transfer of patent rights to Dr. Sakizs new company, the barriers to the future distribution, production, and development of mifepristone have fallen. The transfer of patent rights to Dr. Sakiz irrevocably injures the anti-abortion boycott of Hoechst Marion Roussel.

Mifepristone, which for too long has been kept away from women, is now in good hands. Dr. Sakiz -- a 1994 recipient of the Feminist Majority Foundations Feminist of the Year Award -- has a long history of encouraging scientific developments for the benefit of womens health and of promoting equality for women in the corporate world. Finally, women worldwide will be able to realize the full potential of this medical breakthrough.

Media Resources: Eleanor Smeal, President, Feminist Majority Foundation